18F FACBC an innovative imaging agent for the diagnosis of prostate cancer: a Phase III evaluation in recurrent prostate cancer

在前列腺癌的情况下，需要更好的诊断成像方法。目前的方法既不敏感也不特异，不足以积极指导前列腺癌患者的管理。细胞代谢的增加和氨基酸转运的相关增加是恶性肿瘤生长和增殖的必要条件。[18]FACBC注射液中的活性物质是一种合成的L-亮氨酸类似物，根据临床前研究，已显示其在癌细胞中高度蓄积。氨基酸摄取和整体细胞代谢之间存在已确立的密切关系。该补助金将支持一项针对复发性前列腺癌男性的III期临床研究，以证明一种新型正电子发射断层扫描（PET）药物：[18F]FACBC的疗效。独特的是，这将是第一个在英国单独进行的PET成像III期研究。该项目将汇集7个世界级的临床中心与GE Healthcare，以进一步开发这种潜在的重要新型显像剂。

In the case of prostate cancer there is a need for better diagnostic imaging methods. Current methods are neither sensitive nor specific enough to positively direct prostate cancer patient management.Increased cellular metabolism and an associated increase in amino acid transport is a requirement for the growth and proliferation of malignant tumours. The active substance in the [18]FACBC injection is a synthetic L-leucine analogue that has been shown to accumulate to a high degree in cancer cells based on preclinical studies. There is an established close relationship between amino acid uptake and overall cellular metabolism. This grant will support a Phase III clinical study in men with recurrent prostate cancer in an attempt to demonstrate efficacy of a novel Positron Emission Tomography (PET) agent: [18F]FACBC. Uniquely this will be the first Phase III study in PET imaging solely carried out in the UK. The project will bring 7 world class clinical centres together with GE Healthcare to further develop this potentially important new imaging agent.